Evidence map›Paper›PMID 40419364›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2025

[Research progress and clinical application in the early diagnosis and treatment technology of hepatocellular carcinoma].

Y M Nan, S X Zhao, L D Liu

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Y M NanDepartment of Traditional and Western Medical Hepatology, Department of Gastroenterology, Hebei Medical University Third Hospital, Shijiazhuang 050051, China Hebei Provincial Key Laboratory of Liver Fibrosis mechanism study in Chronic Liver Diseases, Hebei International Joint Research Center for Liver Cancer Molecular Diagnosis, Hebei International Science and Technology Cooperation Base, Shijiazhuang 050051, China.
S X ZhaoDepartment of Traditional and Western Medical Hepatology, Department of Gastroenterology, Hebei Medical University Third Hospital, Shijiazhuang 050051, China Hebei Provincial Key Laboratory of Liver Fibrosis mechanism study in Chronic Liver Diseases, Hebei International Joint Research Center for Liver Cancer Molecular Diagnosis, Hebei International Science and Technology Cooperation Base, Shijiazhuang 050051, China.
L D LiuDepartment of Traditional and Western Medical Hepatology, Department of Gastroenterology, Hebei Medical University Third Hospital, Shijiazhuang 050051, China Hebei Provincial Key Laboratory of Liver Fibrosis mechanism study in Chronic Liver Diseases, Hebei International Joint Research Center for Liver Cancer Molecular Diagnosis, Hebei International Science and Technology Cooperation Base, Shijiazhuang 050051, China.

Funding

Hebei Province Medical Application Technology Tracking Project GZ2024048Key Research and Development Plan Projects of Hebei Province 23377705Dthe Introduction of Foreign Intelligence Program in Hebei Province 2024
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a malignant tumor that endangers human health globally. Diagnosis and treatment at an early stage are the keys to receiving radical treatment and improving survival rates. A clinical solution for HCC diagnosis at an early stage is the combination of serum markers and imaging technology. A basic strategy for screening and diagnosis at an early stage with a favorable cost-effectiveness ratio is the alpha-fetoprotein combined with abdominal ultrasound. The HCC diagnostic rate at an early stage can be improved with AFP combined with des-gamma carboxy prothrombin, aldehyde-keto reductase 1B10, liquid biopsy, and imaging tests. The radical treatment for early-stage HCC has entered a new era of diversification. The effectiveness of radical treatment can assist in improving the combined use of small molecule targeted medications and immune checkpoint inhibitors. The prevention and control of liver cancer will move toward a new stage of greater precision and efficiency with the advancement of biotechnology and policy promotion.

Indexed as

Carcinoma, HepatocellularLiver Neoplasmsalpha-FetoproteinsBiomarkersBiomarkers, TumorEarly Detection of CancerHumansProtein PrecursorsProthrombinacarboxyprothrombinalpha-FetoproteinsBiomarkersBiomarkers, TumorProtein PrecursorsProthrombin

Identifiers

PMID40419364
PMCPMC12899205

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.